Comparative Pharmacology
Head-to-head clinical analysis: BIMZELX versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIMZELX versus YUVEZZI.
BIMZELX vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BIMZELX (bimekizumab) is a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
YUVEZZI is not a recognized drug. No mechanism available.
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
150 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing.
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog